ZyVersa Therapeutics, Inc. (ZVSA) Income Statement
ZVSA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsZVSA revenue and net income
ZVSA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ZVSA quarterly EPS vs estimates
ZyVersa Therapeutics beat the analyst EPS estimate in 1 of the last 6 quarters.
ZVSA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $6,933 | $10,400 | $10,400 | $10,400 | $10,400 |
| Gross profit | — | −$6,933 | −$10,400 | −$10,400 | −$10,400 | −$10,400 |
| Research & development | $1.11B | $1.78B | $3.2M | $5.4M | $2.1M | $6.5M |
| Sales, general & admin | $5.73B | $7.36B | $11.21B | $7.6M | $5.6M | $5.4M |
| Total operating expenses | $6.8M | $9.1M | $14.4M | $13.8M | $7.7M | $11.8M |
| Operating income | −$6.8M | −$9.14B | −$14.4M | −$13.8M | −$7.7M | −$11.8M |
| Interest income | — | — | $457 | — | — | — |
| Interest expense | $513,209 | $269,856 | $457,000 | $427,542 | $821,366 | $516,450 |
| Income before taxes | −$25.8M | −$9.42B | −$107.8M | −$14.9M | −$8.1M | −$12.7M |
| Income taxes | −$851,659 | −$6.7M | −$9.5M | −$745,050 | $821,366 | $516,450 |
| Net income | −$25.0M | −$9.41B | −$98.3M | −$14.0M | −$8.1M | −$12.7M |
| EBITDA | −$25.3M | −$9.14B | −$107.7M | −$14.4M | −$7.3M | −$12.2M |
| EPS (diluted) | −$4.18 | −$11.58 | −$50.53 | −$180.38 | −$281.68 | — |
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $26,078 | $0 | $0 | $15,600 | $15,600 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | $13,039 | $1,733 | $2,600 | $10,439 | $2,600 | $2,600 | $2,600 |
| Gross profit | — | — | — | — | — | $13,039 | −$1,733 | −$2,600 | −$10,439 | $13,000 | −$2,600 | −$2,600 |
| Research & development | $57.6M | $79.2M | $365.1M | $409.9M | $258.9M | $121,245 | $436,043 | $709,049 | $512,937 | $257,110 | $673,943 | $1.2M |
| Sales, general & admin | $1.25B | $472.6M | $1.74B | $1.63B | $1.89B | $1.2M | $1.83B | $2.0M | $2.3M | $1.5M | $2.2M | $3.9M |
| Total operating expenses | $1.3M | $551,858 | $2.1M | $2.0M | $2.1M | $1.3M | $2.3M | $2.8M | $2.8M | $1.8M | $2.9M | $5.1M |
| Operating income | −$1.3M | $4.18B | −$2.1M | −$2.04B | −$2.14B | −$1.3M | −$2.3M | −$2.8M | −$2.8M | −$1.8M | −$2.9M | −$86.3M |
| Interest income | — | — | — | — | — | — | — | — | — | $98 | — | — |
| Interest expense | $132,512 | $132,264 | $131,350 | $130,036 | $119,559 | $138,062 | $131,635 | $58 | $101 | $456,446 | $210 | $314 |
| Income before taxes | −$1.8M | $4.46B | −$20.7M | −$2.21B | −$2.26B | −$1.4M | −$2.4M | −$2.8M | −$2.8M | −$13.9M | −$2.9M | −$86.3M |
| Income taxes | — | — | −$851,659 | — | — | −$2,962 | — | $9,707 | −$596,068 | −$596,068 | −$485 | −$7.8M |
| Net income | −$1.8M | −$678,572 | −$19.8M | −$2.2M | −$2.3M | −$1.4M | −$2.4M | −$2.8M | −$2.8M | −$13.3M | −$2.9M | −$78.5M |
| EBITDA | −$1.7M | −$426,748 | −$20.5M | −$2.1M | −$2.3M | −$1.3M | −$2.3M | −$2.8M | −$2.8M | −$95.1M | −$2.9M | −$5.1M |
| EPS (diluted) | −$0.22 | — | −$2.56 | −$0.46 | −$0.73 | −$1.31 | −$2.43 | −$3.31 | −$4.53 | −$13.68 | −$31.50 | −$4.84 |
| Gross margin | — | — | — | — | — | 50.0% | — | — | −66.9% | 83.3% | — | — |
| Operating margin | — | — | — | — | — | −4,933.7% | — | — | −18,119.5% | −11,386.0% | — | — |
| Net margin | — | — | — | — | — | −5,451.7% | — | — | −18,120.1% | −85,503.2% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ZVSA's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ZVSA financial results
ZyVersa Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $25.0 million. Diluted earnings per share came to −$4.18.
See the ZVSA stock overview for the latest quote and news, or the ZVSA chart for price history and technical indicators.
ZVSA income statement FAQ
Does ZyVersa Therapeutics have revenue?
ZyVersa Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is ZyVersa Therapeutics profitable?
No. ZyVersa Therapeutics reported a net loss of $25.0 million in fiscal 2025.
How much does ZyVersa Therapeutics spend on research and development?
ZyVersa Therapeutics spent $1.1 billion on research and development in fiscal 2025.
What are ZyVersa Therapeutics's earnings per share?
ZyVersa Therapeutics earned $-4.18 per diluted share in fiscal 2025, compared with $-11.58 a year earlier.
When does ZyVersa Therapeutics's fiscal year end?
ZyVersa Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.